30 closest matches · ranked by relevance
Malignant Solid Tumor - Malignant Nervous System Neoplasm
Primary: Phase 1: Maximum Tolerated Dose of Cabazitaxel — 30 mg/m^2
Central Nervous System Nongerminomatous Germ Cell Tumor · Childhood Germinoma
Primary: 3-year Progression-free Survival (PFS) Rate of Patients With Nongerminomatous Germ Cell Tumor (NGGCT) Who Were Treated With Reduced Dose Whole Ventricular-field…
Central Nervous System Tumors
Primary: Measurement of Number of Adverse Events — 4; 6; 3; 5 Adverse events
Central Nervous System Tumor, Pediatric
Primary: 2-yr Overall Survival — 0.70 probability
Brain Tumors
Primary: Progression Free Survival — 70 percentage of no progression
Various Advanced Cancer
Primary: Number of Safety Lead-In Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0 Number of participants
Childhood Atypical Teratoid/Rhabdoid Tumor
Primary: Event-free Survival — 0.3401; 0.4500 Estimated probability
Recurrent Childhood Anaplastic Astrocytoma · Recurrent Childhood Brain Stem Glioma · Recurrent Childhood Ependymoma
Primary: Relative Phosphorylation of ERBB2 (Molecular Biology Objective) — .21; .50 ratio
Central Nervous System Neoplasms · Medulloblastoma
Primary: Percentage of Participants With an Objective Response and Long-term Stable Disease — 0; 11.1; 10.5; 0 percentage of participants
Pediatric Central Nervous System Tumor
Primary: Sensitivity and Specificity of Tozuleristide Fluorescence to Detect Tumor in Equivocal (Ambiguous) Tissue During Surgery When Imaged With the Canvas System — 79.8; 34.7…
Brain Tumor · Low Grade Glioma · Astrocytoma
Primary: Endocrine Dysfunction — 14.5; 20.2 percentage of participants
Anaplastic Medulloblastoma · Medulloblastoma · Supratentorial Embryonal Tumor, Not Otherwise Specified
Primary: Number of Patients Who Have Either a Complete Response (CR) Rate or No Complete Response Rate — 13; 15; 16; 15 Participants — p=0.35
Brain Tumor · Central Nervous System Tumor
Primary: Event-free Survival — 1; 1; 0; 0 participants
Diffuse Intrinsic Pontine Glioma
Primary: Two Year Survival of Pediatric Patients With Diffuse Pontine Gliomas — 14.29 Percentage of patients
Brain Tumor · Central Nervous System Tumor
Primary: Marginal-failure Rate — 0 percentage of failure rate
Glioblastoma Multiforme · Anaplastic Astrocytoma · Anaplastic Oligodendroglioma
Primary: Number of Patients Who Experienced Dose-limiting Toxicities (DLTs) — 3 Participants
Central Nervous System Tumors · Brain Tumors
Primary: Local Tumor Control — 0.966; 0.959; 1.000; 1.000 Proportion of patients
Brain Cancer
Primary: Number of Participants With High-grade Astrocytoma and Diffuse Pontine Tumors Achieving One Year Progression Free Survival. — 5; 6 Participants
Anaplastic Astrocytoma · Central Nervous System Neoplasm · Glioblastoma
Primary: One Year Overall Survival — 0.7208 Estimated probability
Central Nervous System Tumor, Pediatric · Neuroblastoma
Primary: Therapy Completion Rate — .40 proportion of participants
Central Nervous System Neoplasm · Pineoblastoma · Recurrent Medulloblastoma
Primary: Overall Survival — 2.43; 13.6 percent probability
Advanced Non CNS Tumors
Primary: Percentage of Participants Who Experienced a Dose-limiting Toxicity (DLT) — 0.0; 0.0; 100.0; 100.0 Percent of participants
Malignant Glioma · Anaplastic Astrocytoma · Anaplastic Oligoastrocytoma
Primary: Percentage of Participants With Unacceptable Toxicity — 0 percentage of participants
Childhood CNS Primitive Neuroectodermal Tumor
Primary: Number of Participants With Objective Response — 3; 1; 1; 7 Participants
Recurrent and Refractory Solid Tumors
Primary: Phase 1: Maximum Tolerated Dose (MTD) of Lenvatinib in Combination With Everolimus — 11 milligram per square meter (mg/m^2)
Brain and Central Nervous System Tumors
Primary: Progression-Free Survival (PFS) in ERBB2-Negative Tumors Compared to ERBB2-Positive Tumors — 79.2; 83.3; 69.6; 86.7 probability of PFS at 2 years — p=0.8001
Central Nervous System Lymphoma
Primary: Complete Remission Rate After Primary Chemotherapy — 23; 30; 49 Percentage of participants
High Grade Glioma
Primary: Event-Free Survival (EFS) as Assessed by the Central Radiology Review Committee (CRRC) — 11.79; 8.21 months — p=0.1292
High Grade Glioma · Ependymoma
Primary: Safety of the Optune NovoTTF-200A System When Used Alone in Pediatric Patients With Recurrent High-grade Gliomas. — 0 Participants
Brain Tumor · Central Nervous System Tumor
Primary: Short Term Feasibility Success — 25 participants